Introduction {#sec1-1}
============

Colorectal carcinoma (CRC) is one of the leading causes of mortality worldwide. It is the third most common cancer in males and second in females globally and recorded as second major cause of cancer-related deaths worldwide (Bray et al., 2018). In India CRC is fifth most common cancer in females and forth in males with incidence rate of 3.1% and 5.8% respectively (Bray et al., 2018). There is an increasing incidence of CRC in India. CRC is a heterogenous disease, influenced by genetic and epigenetic alterations and the heterogenicity is due to several pathways involved in CRC tumorigenesis (Colussi et al., 2013). CRC patients show a significant difference in prognosis and individual treatment responses even when presenting at same clinical stage. Multiple factors deregulate the expression of cancer related genes (like APC, KRAS, BRAF, TP53, SFRPs MLH1, MSH1) and promoter methylation mediated silencing is one of them (Armaghany et al., 2012; Thiel et al., 2013; Fearon and Vogelstein, 1990; Wheeler et al., 2000). Secreted Frizzled Related Protein1 (*SFRP1*) gene is known for its ability to negatively modulate the Wnt signaling cascade (Mii and Taira, 2011). *SFRP1* gene codes for *SFRP1* protein that works as an antagonist of Wnt protein and plays a significant role in the regulation of Wnt/βcatenin signaling pathway. β-catenin dependent canonical WNT signaling maintains crypt stem cell compartment in the intestine but overactivation of this pathway by genetic or epigenetic changes has been seen in colorectal carcinoma (Novellasdemunt et al., 2015). This Wnt/βcatenin pathway also plays important role in tumorigenesis of several other types of cancers like breast, ovarian, gastrointestinal cancer (Clevers and Hans, 2006; Huang et al., 2006; Zhan et al.,2006). In CRC, *SFRP1* gene expression is found to be downregulated due to aberrant methylation in its promoter region and this promoter methylation is a common epigenetic alteration found in human cancers including colorectal carcinoma (Suzuki et al., 2004; Jones and Jomary, 2002). CpG islands are susceptible for methylation and since most of gene promoter regions are CpG island rich, it implies that promoter regions are most susceptible for hypermethylation and thus, promoter methylation leads transcriptional silencing of the gene (Nandakumar et al., 2011). If promoter hypermethylation occurs in tumor suppressor gene it may lead to tumorigenesis. Promoter hypermethylation mediated epigenetic silencing of *SFRP1* gene is a major cause of downregulation of *SFRP1* protein level and leads overactivation of Wnt signaling in CRC. Methylation based molecular makers are successfully being used in routine as prognostic/predictive marker for better patient management in various cancer Eg. MGMT in Gliomas (Weller et al., 2010). Some studies have also described value of *SFRP1* as prognostic/predictive biomarker in cancer (Leygo et al., 2017; Zheng et al., 2015). The aim of our study was to look for promoter hypermethylation of *SFRP1* gene in CRC, and find its prognostic significance. It explores for association of promoter methylation of *SFRP1* gene with clinicopathological features of CRC and patient survival.

Materials and Methods {#sec1-2}
=====================

Patients and tissue specimen {#sec2-1}
----------------------------

We enrolled 54 histopathologically confirmed cases of CRC, who underwent curative surgery in Departments of Surgical Gastroenterology and Surgical Oncology, Dr. R M L Institute of Medical Sciences Lucknow, UP, India. Of these 54 cases 28 (51.85%) case were stage II and 26 (48.15%) cases were stage III at the time of diagnosis (Lippincott-Raven et al., 1998). After histopathological examination (HPE), the FFPE tissue blocks were taken for molecular analysis. HPE (staging and grading) were done by standard procedure. Patient demographic and histopathological details and follow up were recorded. This study was approved by Institutional Ethics Committee (IEC no-8/15) of Dr. RMLIMS, Lucknow, and written informed consent was taken for all cases included in this study. The selection of tumor and non-tumor regions was done by examining Hematoxylin - Eosin (H and E) stained sections. Patient follow up and mean survival was noted up to the close of study observations (July 2018) or the death of the patient which was earlier.

Genomic DNA extraction {#sec2-2}
----------------------

DNA extraction from FFPE tissues were done by using QIAamp FFPE tissue Kit, REF no. 56404 (Qiagen, Hilden, Germany) by following manufacturer's protocol. DNA quality and quantity checked by spectrophotometrically. Purity and integrity checked by agarose gel electrophoresis in 0.8% agarose gel.

Bisulfite modification of DNA {#sec2-3}
-----------------------------

The genomic DNA isolated from the CRC tumor and adjacent normal tissue were subjected to bisulfite methylation analysis. Bisulfite conversion of DNA was done by using Epitect Bisulfite kit (Cat No./ID: 59104 Qiagen, Hilden, Germany) by following manufacturer's protocol designed for processing DNA isolated from FFPE tissue samples. Briefly, the 20µl solution of DNA (500ng- 2µg) mix with 35 µl of DNA protecting buffer and 85 µl bisulfite mix and incubated for conversion in thermo cycler at recommended temperature. After completion of bisulfite conversion reaction, 310 µl freshly prepared buffer BL containing 10 µg/ml carrier RNA (Carrier RNA increases binding of DNA to the spin-column membrane) added to sample then sample transferred to spin columns after that washing by wash buffer. Followed by desulphonation step performed by adding 500 µl de-sulfonation buffer BD to the spin columns and incubate for 15 min at room temperature. Then sample twice washed by wash buffer. Then final bisulfite converted DNA eluted in 20 µl elution buffer. Bisulfited converted DNA used for MS-PCR analysis within 24 hours.

Methylation specific PCR (MS-PCR) {#sec2-4}
---------------------------------

Methylation specific PCR was set up according to the method described by Herman et al., (1996). 2.5 µl bisulfite converted DNA was amplified using methylation specific primers that specifically recognized either the unmethylated or methylated *SFRP1* gene sequence after bisulfate conversion (Takada et al., 2004) . Sequences of the primers for MS-PCR of the *SFRP1* promoter region were commercially procured. The sequences for Methylated primer were Forward: 5\'-TGTAGTTTTCGGAGTTAGTGTCGCGC-3\', Reverse : 5\'- CCTACGATCGAAAACGACGCGAACG-3\' (126bp); unmethylated primers, Forward- 5\'-GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT-3\', Reverse:5\'CTCAACCTACAAATCAAAAACAACACAAACA-3\' (135bp). All PCR reactions were performed using AmpliTaq Gold PCR master mix PCR cycling conditions were as following: initial denaturation at 95°C for 10 min then 35 cycles consisting of three steps: 95°C for 10s, respective annealing temperature for 30s at 59°C, extension at 68°C for 10s followed by a final extension at 72°C for 10 min. The annealing temperature for amplification of methylated and un-methylated *SFRP1* promoter region was 59°C, and 58°C respectively. Methylated and un-methylated bisulfite converted human control DNA procured from Qiagen, Hilden, Germany was used as positive control for methylation and unmethylation.

SFRP1 Promoter methylation sequencing analysis {#sec2-5}
----------------------------------------------

Validation of MS-PCR results and methylation pattern of CpG in promoter region was done by bisulfite sequencing using the method defined by Susan et al., (1994). MS-PCR products from tumor and normal tissues were sequenced by using ABI sequencing platform Genetic analyzer 3500, and sequence analysis and alignment was done using Bioedit software and CLUSTALW online tool.

Statistical analysis {#sec2-6}
--------------------

Statistical analyses was done by using SPSS software (version 20). Chi square test was used to analyze the statistical association between clinic-pathological data and methylation status of *SFRP1*. Kaplan Meier survival curve and Log-rank test were used for survival analysis. To evaluate the prognostic impact, all clinicopathologic variables were evaluated along with *SFRP1* methylation status by using univariate cox proportional hazard model analysis. P-value \<0.05 was considered as significant.

Results {#sec1-3}
=======

Clinicopathological characteristics {#sec2-7}
-----------------------------------

The clinicopathological details are summarized in [Table 1](#T1){ref-type="table"}. The median age of patients at the time of diagnosis was 49 years (range 18-76 years). Of these 33 (61.1%) were male and 21 (38.9%) were female patients (M:F = 1.57:1). 28 (51.85%) cases were of CRC stage II, and 26 (48.15%) stage III. The tumor site was right colon in 18 (33.3%), left colon (excluding rectum) in 20 (37%) and rectum in 16 (29.6%) cases. Histologically, 47 (87%) tumors were infiltrating adenocarcinoma NOS, 7 (13%) were mucinous adenocarcinoma. The tumor grade was well differentiated in 32 (59.3%) cases, moderate differentiation in 13 (24 %) and poor differentiation in 9 (16.6%) cases. Clinical follow up ranging from 12 to 56 months was available in these cases.

###### 

Clinicopathological Characteristics of CRC Cases and Their Association with Methylation

  Variable                    Categories                        No. of cases   Methylation status of *SFRP1* gene promoter   *p-value*    
  --------------------------- --------------------------------- -------------- --------------------------------------------- ------------ -------
  Age group                   \<50 year                         27             9 (33.3)                                      18 (66.7)    0.54
  \>50 year                   27                                6 (22.2)       21 (77.8)                                                  
  Gender                      Male                              33             8 (24.2%)                                     25 (75.8%)   0.54
  Female                      21                                7 (33.3%)      14 (66.7%)                                                 
  Tumour Stage                T2                                9              3 (33.3%)                                     6 (66.7%)    0.77
  T3                          23                                7 (30.4%)      16 (69.9%)                                                 
  T4                          22                                5 (22.7%)      17 (77.3%)                                                 
  Lymph-node involvement      pN0                               28             11 (39.3%)                                    17 (60.7%)   0.05
  pN1-3                       26                                4 (15.4%)      22 (84.6%)                                                 
  Histological type           Infiltrating adenocarcinoma NOS   47             13 (27.7%)                                    34 (72.)     1
  Mucinous adenocarcinoma     7                                 2(28.6%)       5 (71.4%)                                                  
  Tumour grade                Poorly differentiated             9              3 (33.3%)                                     6 (66.7%)    0.83
  Moderately differentiated   13                                4 (30.8%)      9 (69.2%)                                                  
  Well differentiated         32                                8 (25%)        24 (75%)                                                   
  Tumour location             Colon                             38             10 (26.3)                                     28 (73.7)    0.747
  Rectum                      16                                5 (31.2%)      11 (68.8%)                                                 

Table 1- Showing association of clinico-pathological parameters in relation to methylation status of SFRP1 gene using Chi square test (significant p-value \<0.05).

SFRP1 gene promoter methylation in tumor tissue {#sec2-8}
-----------------------------------------------

We analyzed *SFRP1* gene promoter methylation status in tumor tissue and adjacent normal tissue. In 39 out of 54 (72.2%) CRC cases *SFRP1* gene was methylated while in 15/54 (27.8%) cases it was unmethylated. Whereas in only 2 out of 28 (7%) cases adjacent non tumor tissue showed methylated *SFRP1* gene. Thus a significant difference in methylation status (P\<0.0001) was present between tumor and non-tumor tissue ([Figure 1](#F1){ref-type="fig"}). Methylated in relation to clinical stage was noted in 60.7% cases of stage II and 84.6 % cases of stage III tumor. To ascertain the methylation status of CpG sites present within promoter region of *SFRP1* gene, we performed Bisulfite Sequencing of the 126 bp DNA fragment of *SFRP1* gene amplified by MS-PCR in representative cases. Bisulphite sequencing showed methylated Cytosine nucleotide in the CpG sites. This 126 bp DNA sequence, in the cases showing methylated *SFRP1* in MS-PCR, contained 22 CpG cites within which most of the cytosine nucleotides were methylated ([Figure 2](#F2){ref-type="fig"}).

![Promoter Methylation Analysis of *SFRP1* Gene in CRC Tumor Tissue by Methylation Specific Polymerase Chain Reaction (MS-PCR). MS-PCR amplified product run in 4.0% agrose gel. (a), Shows distinct band of methylated frgment in lane 2,4,6 and their intensity hingher than respective unmethylated band lane 3,5,7 in 3 Colorectal carcinoma tumour tissue. 20bp ladder in lane 1 and 50bp ladder in lane 8; (b), Shows the methylated DNA band in a CRC tumour tissue (lane 5) with control, positive control unmethylation (lane 2), positive control methyaltion (lane 3) and nigative control NTC ( lane 6) with 50 bp ladder (lane 1). Size of Methylated and Un-methylated fragment is 126bp and 135bp respectively. M (Methylation specific polymerase chain reaction), U (Un-methylation specific polymerase chain reaction), L (Ladder) NTC (Non Templete Control, water used instead of DNA template.](APJCP-20-1571-g001){#F1}

![*SFRP1* gene promoter methylation analysis by bisulphite sequencing. (a), Chromatogram of methylated SFRP1 gene promote -- Bold blue C represents methylated cytosine that's remained unchanged during bisulfite conversion due to its methylation and C represents un-methylated cytosine that converted to thymine represented T, and CG in round corner rectangle represents CpG sites; (b), Chromatogram in a case of un-methylated SFRP1 gene t represented un-methylated cytosine that converted to thymine during bisulphite conversion. Arrow marked-"a" is sequence is normal 126bp of DNA sequence of SFRP1 gene of Homo sapiens *SFRP1* gene (NCBI Reference Sequence: NM_003012.4), "b" Bisulfite converted DNA sequence of methylated *SFRP1* gene of CRC case "c" chromatogram of bisulfite sequencing](APJCP-20-1571-g002){#F2}

SFRP1 promoter methylation associated with lymph node invasion {#sec2-9}
--------------------------------------------------------------

Promoter methylation status of *SFRP1* gene was compared with patient's clinicopathological characteristics such as age, gender, tumor location, lymph node involvement, tumor stage, and tumor grade ([Table 1](#T1){ref-type="table"}). Chi square test results show that lymph node metastasis was significantly associated with methylation status of *SFRP1* gene in the tumor. Lymph node involvement (pN1-3) was noted in 84.6% cases with methylated *SFRP1*. Location of tumor was not associated with methylation status. A higher frequency of methylation was observed in patients over 60 years age, however this was not statistically significant.

Methylation of SFRP1 decreases the overall survival {#sec2-10}
---------------------------------------------------

Based on the observed methylation status of *SFRP1* gene in the tumor tissue, methylated and unmethylated groups were defined. Follow-up in 54 patients ranging from 12 month to 56 month (median follow-up 28 months) 18 CRC patients had died due to disease related event and advanced tumor stage and 12 patients lost to follow-up. The overall mean survival of unmethylated and methylated group was 45.173 months and 22.318 months respectively survival curve in ([Figure 3a](#F3){ref-type="fig"}). The combined estimated OS of both the groups were 33.461 months. Unmethylated groups survival was significantly better as compare to methylated group (p= 0.010 by Log rank test) and poor survival associated with methylation of *SFRP1*. We also analyzed survival of CRC patients with reference of 8 deferent conventional pathological factors such as Age group, Gender, Tumor stage, Clinical stage, Lymph node status, Differentiation of tumor and Tumor subtype ([Table 3](#T3){ref-type="table"}). Kaplan-Meir survival analysis results shows survival is dependent on many factors but it was majorly influenced by lymph node status and methylation of *SFRP1*. If we talk about survival on the basis of clinical stage II and III the mean survival was 40.96 and 26.88 months respectively p=0.135 by log rank test ([Figure 3b](#F3){ref-type="fig"}). To explore the contribution of these variables and evaluation of their influence as potential prognostic marker, all these variables were analyzed by univariate cox regression model analysis. In univariate analysis, only *SFRP1* methylation status could be verified as an independent prognostic factor, (HR = 17.313, 95% CI: 2.021-148.290, and *P-value* = 0.009, [Table 2](#T2){ref-type="table"}). Univariate cox model suggesting, among these variables, *SFRP1* methylation can serve as an independent prognostic indicator of poor survival in CRC.

###### 

Association between Clinicopathological Characteristics and Prognosis of the Disease by Using Univariate Cox Regression Analysis

  Variables                                   Categories                        No. of cases   No of Events (deaths)   HR                95% CI\# (Lower-Upper)
  ------------------------------------------- --------------------------------- -------------- ----------------------- ----------------- ------------------------
  Age group                                   \<50 year                         27             11                      1                 Ref.
  \>50 year                                   27                                7              0.672                   (0.183-2.475)     
  Gender                                      Male                              33             13                      1                 Ref.
  Female                                      21                                5              0.308                   (0.089-1.063)     
  Histological type                           Infiltrating adenocarcinoma NOS   47             14                      1                 Ref
  Mucinous adenocarcinoma                     7                                 4              2.404                   (0.664-8.701)     
  Tumor grade                                 Poorly differentiated             9              4                       1                 Ref.
  Moderately differentiated                   13                                3              0.267                   (0.042-1.681)     
  Well differentiated                         32                                11             0.333                   (0.082 -1.356)    
  Tumor stage                                 pT2                               9              3                       1                 Ref.
  pT3                                         23                                6              0.387                   (0.075-1.982)     
  pT4                                         22                                9              0.755                   (0.144-3.955)     
  Tumor location                              Colon                             38             11                      1                 Ref.
  Rectum                                      16                                7              1.15                    (0.391-3.385)     
  Lymph node involvement                      pN0                               28             6                       1                 Ref.
  pN1-3                                       26                                12             1.281                   (0.391-4.471)     
  Methylation status of SFRP1 gene promoter   Un-methylation                    15             2                       1                 Ref.
  Methylation                                 39                                16             17.313                  (2.021-148.290)   

HR, (Hazard Ratio); \#, Hazard Ratio (95% Confidence Interval); Ref., taken as reference

###### 

Kaplan-Meier Survival Analysis with References to Clinicopathological Characteristics.

  Variables                       Categories                        No. of cases   No of Events (death)   Mean Survival in months   P value
  ------------------------------- --------------------------------- -------------- ---------------------- ------------------------- ---------
  Methylation status of *SFRP1*   Un-methylation                    15             2                      45.17                     0.01
  methylation                     39                                16             22.32                                            
  Age group                       \>50 year                         27             7                      34.68                     0.472
  \<50 year                       27                                11             28.66                                            
  Lymph-node                      pN0                               28             6                      40.96                     0.135
  involvement                     pN1-3                             26             12                     26.88                     
  Gender                          Male                              33             13                     29.34                     0.146
  Female                          21                                5              29.75                                            
  Tumour grade                    Poorly differentiated             7              3                      27.10                     0.68
  Moderately differentiated       14                                4              29.33                                            
  Well differentiated             26                                7              32.78                                            
  Tumour stage                    pT2                               9              3                      26.99                     0.284
  pT3                             23                                6              37.81                                            
  pT4                             22                                9              18.95                                            
  Histological type               Infiltrating adenocarcinoma NOS   47             14                     34.70                     0.142
  Mucinous adenocarcinoma         7                                 4              24.85                                            
  Location of tumour              Colon                             38             11                     26.17                     0.931
  Rectum                          16                                7              34.06                                            

![a, Kaplan-Meier survival analysis curve on the basis of methylation status of SFRP1 gene promoter region shows significance difference between methylated and un-methylated group p= 0.010 (Log rank test); b, Kaplan-Meier survival analysis curve on the basis of clinical stage II vs III P=0.135.](APJCP-20-1571-g003){#F3}

Discussion {#sec1-4}
==========

Wnt signaling plays important role in embryonic development where it determines the cell fate, cell proliferation and cell migration (Clevers and Hans, 2006; Zhan et al. 2016). In life, Wnt signaling also controls tissue regeneration in adult bone marrow, skin and intestine (Goessling et al., 2009). Wnt signaling maintains intestinal stem cells by proliferation and differentiation. It is also involved in carcinogenesis of various tumors including CRC (Mii and Taira, 2011; Zhan et al., 2016; Zhou et al., 2015; Clevers and Hans, 2006; Huang et al., 2006). *SFRP1* gene is known for its ability to negatively modulate the Wnt/β-catenin signaling cascade. Promoter methylation downregulates the expression of *SFRP1* gene in CRC (Jones and Jomary, 2002; Suzuki et al., 2004; Shih et al., 2006, Fukui et al., 2005) Silencing of *SFRP1* gene, allows constitutive WNT signaling via binding to Wnt protein and inhibits its binding to Wnt-frizzled receptor, consequently altering the proliferation and differentiation of tumor cells. Limited studies have looked in to the association of *SFRP1* methylation with clinicopathological characters and survival in CRC. Studies done on other tumors suggest that methylation of *SFRP1* gene can serve as epigenetic diagnostic, prognostic and predictive marker in liver, gall bladder, upper gastrointestinal tract and lung cancers (Kim et al., 2016; Mo et al., 2018; Suzuki et al., 2002; Müller et al., 2004; Zou et al., 2005; Su et al., 2009) In the present study, we have studied promoter methylation status of *SFRP1* gene in CRC patients and its association with various clinicopathological characteristics. We found that *SFRP1* was frequently methylated in tumor tissue compared with adjacent non tumor tissues. The frequency of *SFRP1* gene promoter methylation in our patients was 72.2%. Previous studies, have shown a frequency ranging from 52-95% in colorectal cancer (Rawson et al., 2011; Barták, 2017; Zhou et al., 2015; Meng et al., 2011; Dallol et al., 2012; Salehi et al., 2012). In present study we noted a slightly higher incidence of hypermethylation of *SFRP1* in male patients than females (75.8% vs. 66.7%), however this difference was not statistically significant (p=0.54). The frequency of methylation was not influenced by the histological subtype of tumor. Infiltrating adenocarcinoma NOS and mucinous adenocarcinoma showed *SFRP1* gene promoter methylation frequency of 72.3% and 71.4% respectively. In 84% cases with lymph node metastasis, *SFRP1* gene methylation was noted which was significant (P=0.05). Other clinicopathological characters such as age, gender, tumor, location, tumor stage, tumor type, grade of tumor did not show any significant association with methylation status of *SFRP1* gene. Our data suggests that *SFRP1* promoter methylation is an epigenetic prognostic marker for poor survival in stage II and III CRC. The patients in the methylated group had shorter mean overall survival (22.318 months) as compared to the un-methylated group (45.173 months). A possible reason for shorter overall survival with methylated *SFRP1* gene in CRC could be that promoter methylation reduces expression of *SFRP1* gene allowing constitutive WNT signaling that may help tumor cell to proliferate. Epigenetic inactivation of SFRP genes allowing constitutive WNT signaling in colorectal cancer has been previously described by Suzuki et al., (2004). *SFRP1* gene has also been studied in other tumors such as Head and neck squamous Cell carcinoma, breast cancer and found to indicate poor patients survival (Alsofyani et al., 2016, Veeck et al., 2008, Kang et al., 2014) An implication of this findings can also be explored for targeted therapy in CRC using recombinant *SFRP1* (Cooper et al., 2012).

This study has some limitations such as smaller sample size and shorter duration of follow-up. However even then the findings obtained are important with prognostic significance. Similar studies with larger sample size and longer follow-up would be helpful to substantiate our findings.

In conclusion our study shows that promoter methylation of *SFRP1* gene occurs frequently in Colorectal Carcinoma. This *SFRP1* promoter methylation is significantly associated with lymph node invasion and poor survival outcome in stage II and III CRC patients and it appears to be a poor prognostic marker.
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